The purpose of this meta-analysis was to determine the additional value of neoadjuvant, concurrent, and/or adjuvant chemotherapy to radiation in the treatment of locally advanced nasopharyngeal carcinoma (NPC) with regard to the overall survival (OS) and the incidence of local-regional recurrences (LRR) and distant metastases (DM).
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a malignant disease of the head and neck area with a high prevalence in Southeast Asian and North African populations, whereas this disease is relatively rare in western Europe and the United States. There is increasing evidence that the addition of chemotherapy to radiotherapy provides survival benefit in many solid tumors, 1, 2 including NPC. In particular, since the publication of the results of the Intergroup study, 3 concomitant chemoradiotherapy and adjuvant chemotherapy has been widely accepted as standard in the treatment of patients with stage III and IV NPC. 4, 5 In several metaanalyses regarding non-nasopharyngeal head and neck cancer, a significant improvement of the overall survival was noted when chemotherapy was given concomitantly with radiation therapy. However, no significant benefit was found for adjuvant and/or neoadjuvant chemotherapy. 1, 6 Taking these results into account, the question arises as to whether the adjuvant part of the Intergroup schedule has a significant impact on the outcome of these patients, particularly because the compliance of this part of the treatment was relatively low. 3 Conversely, given that NPC has a greater propensity for distant metastases and is a more chemotherapysensitive tumor than squamous cell carcinoma of other head and neck sites, sequential chemotherapy may still be beneficial in NPC. After the publication of the Intergroup study, the results of a number of other randomized studies on the additional value of chemotherapy to radiation in NPC has become available. Therefore, this systematic review based on published literature was undertaken to determine whether neoadjuvant, concomitant, and adjuvant chemotherapy lead to an improvement of the overall survival, a reduction in locoregional recurrences, and a reduction in the frequency of distant metastases.
PATIENTS AND METHODS

Trial Selection
Studies eligible for this systematic review were those in which patients with NPC were randomly assigned to receive radiotherapy alone or radiotherapy combined with chemotherapy. For this analysis, all forms of chemotherapy in addition to radiotherapy were included. Subgroup analysis was used to explore possible differences related to different chemotherapy regimens. For this purpose, three subgroups were defined. The first group of trials consisted of studies investigating the additional value of neoadjuvant chemotherapy without concomitant chemotherapy (neoadjuvant group). The second group consisted of trials that studied new regimens containing at least concomitant chemotherapy with or without adjuvant chemotherapy (concomitant group). The third group consisted of studies that investigated the value of adjuvant chemotherapy in addition to radiation (adjuvant group) without concomitant chemotherapy. The trials had to have included only patients with histologically proven NPC (WHO type 1 to 3), without distant metastases at presentation and who had been treated with definitive radiation. Adequate doses of radiotherapy had to be used in both arms equivalent to at least 66 Gy, with conventional fractionation to the primary lesion. Enrollment had to be completed between January 1975 and December 2000.
Literature Search Strategy
The meta-analysis aimed to include published trials. Electronic databases (Medline, CancerLit, Excerpta Medica, and Biosis) were searched to identify potentially eligible trials. In addition, reference lists of published reports, review articles, and relevant books were searched.
Statistical Analysis
The main end point of this meta-analysis was overall survival, defined as the time from random assignment to death. Secondary end points were the incidence of local and/or regional recurrence and distant metastases.
Results regarding the overall survival were expressed as hazard ratios (HRs) with 95% CIs. A hazard ratio less than 1 indicated improved survival for the combined-modality treatment compared with radiotherapy alone. If the hazard ratio and its variance were available directly for an individual trial, then these values were used. If either statistics were not available, indirect methods were used (eg, by using the graphical information of the survival curves and/or the P values). The methods to extract these summary statistics indirectly have been described in detail by Parmar et al. 7 Comparison between radiotherapy and radiotherapy plus chemotherapy was performed with the pooled log-rank test. The observed minus expected number of deaths (O Ϫ E) and its variance were calculated for each trial and used to calculate the individual hazard ratio for each individual trial as well as a pooled hazard ratio for all trials together using the fixed-effect model. The weight of each trial in the pooled analysis was proportional with the (O Ϫ E) variance. The absolute difference in the overall survival after 3 years was calculated using the pooled HR and the survival rate in the radiotherapy-alone group assuming proportional hazards. Pooled Kaplan-Meier curves were plotted using the same methods.
For the incidence of locoregional recurrence and distant metastasis, the data provided in the trial reports were mainly insufficient to calculate the HR because in most reports, only the absolute number of events was mentioned, whereas no information was available about the time to event. Therefore, the relative risk was used as a summary statistic for the secondary end points, which, in contrast to the HR, does not take into account the time to event. For comparison among treatment groups, the Mantel-Haenszel test was used. The consistency of the treatment effects across the studies was tested by using a 2 test for statistical heterogeneity. In addition to the main meta-analysis, trials were grouped according to the timing of chemotherapy. Tests for interaction were performed to determine whether patients had more benefit from neoadjuvant, concomitant, or adjuvant chemotherapy. All statistical tests were two sided.
RESULTS
Trials
A total of 10 randomized trials and one metaanalysis 3,8-17 were identified in which patients were randomly assigned to radiotherapy alone and radiotherapy in combination with chemotherapy. The characteristics of these studies are listed in Table 1 . The majority of patients were included after 1990. Two studies were small and included fewer than 100 patients. 10, 14 In these 10 studies, 2,450 patients were randomly assigned, of whom 1,224 received radiotherapy alone and 1,226 received combinedmodality treatment. There were four studies investigating the addition of neoadjuvant chemotherapy without concomitant chemotherapy to radiation, including a total of 1,209 patients. [12] [13] [14] 16 In three studies, including 781 patients, concomitant chemoradiotherapy with or without adjuvant chemotherapy was compared with radiotherapy alone.
3,9,15 In one of these studies, 3 adjuvant chemotherapy was part of the combined-modality approach. In two studies, 11,17 adjuvant chemotherapy was added to radiation alone, whereas in one additional study, two courses of neoadjuvant and four courses of adjuvant chemotherapy were added to radiation. 10 For practical reasons, this latter study was pooled together with the adjuvant studies based on the number of adjuvant courses. Thus, a total of 463 patients were included in the adjuvant group.
Quality of Studies
Two observers evaluated the quality of the studies included in the analysis independently. The following items were scored: description of selection criteria, withdrawals after randomization, randomization procedure, power analysis before the study, distribution of pretreatment variables, and intention-to-treat analysis.
In nine of 10 studies, the selection criteria were described adequately. In one study, the eligibility criteria for chemotherapy were not mentioned. 10 In one study, of 193 patients registered, 147 were eligible for primary analysis of survival and toxicity. 3 In another study, five of 82 patients were excluded from the analysis because the treatment protocol had not been completed. 10 In three studies, the randomization procedure was described clearly and consisted of computer-generated numbers into one of the two arms (two studies) or block randomization using sealed envelopes (one study). A power analysis before the study to assess the required number of patients, including the expected difference in the main end point and the ␣ and ␤ values, was reported in only five articles.
9,11-13, 15 In four studies, it was stated that the analysis was carried out according to the intention-to-treat principle.
9,11,13,15 Tables comparing the pretreatment characteristics in both arms were present in all articles. Only three studies mentioned the HR for the overall survival with the 95% CI.
3,11,17 In one study, no information regarding the overall survival was available.
9
Overall Survival
Data regarding the overall survival of nine studies were available. The overall survival was not reported in one study. 9 For the remaining nine studies, a significant benefit in favor of the addition of chemotherapy was found (P ϭ .01). The HR of death for all studies was 0.82 (95% CI, 0.71 to 0.95; Fig 1) . This corresponds with an absolute survival benefit of 4% after 3 years. A significant interaction was found (P ϭ .02) for the sequence of radiotherapy and chemotherapy. In the concomitant group, a significant benefit was found in favor of the combined treatment (P ϭ .004) with an HR of death of 0.48 (95% CI, 0.32 to 0.72), corresponding with an absolute survival benefit of 20% after 3 years (Fig 2A) . This subgroup analysis was based only on the two studies with available data on overall survival. When the Intergroup study was excluded from this subgroup analysis, only one study remained with available data on the overall survival (HR, 0.56; 95% CI, 0.33 to 0.93).
15 No significant beneficial effect on the overall survival was found for neoadjuvant and/or adjuvant chemotherapy (Figs 2B and 2C ).
Locoregional Recurrence
Data regarding the absolute number of locoregional recurrences were available in all studies. A significant overall benefit in favor of the addition of chemotherapy was found (P Ͻ .0001) for all studies (relative risk [RR], 0.68; 95% CI, 0.58 to 0.79; Fig 3) . There was a trend toward a stronger benefit with the use of concomitant chemoradiotherapy as compared with neoadjuvant and adjuvant chemotherapy (test for interaction, P ϭ .08). In the three studies that compared radiotherapy with concomitant chemotherapy, a significant benefit was found in favor of the combined treatment (P Ͻ .0001), with an RR of 0.47 (95% CI, 0.33 to 0.67). When the Intergroup study (concomitant plus adjuvant chemotherapy) was excluded from this subgroup analysis, the RR for concomitant chemotherapy alone was 0.54 (95% CI, 0.34 to 0.84), which was statistically significant (P ϭ .006). The addition of neoadjuvant chemotherapy to radiation resulted in a significant reduction (P ϭ .005) of the incidence of locoregional recurrences (RR, 0.74; 95% CI, 0.60 to 0.91). However, no significant beneficial effect on the incidence of locoregional recurrence was found for adjuvant chemotherapy (RR, 0.79; 95% CI, 0.55 to 1.14).
Distant Metastases
Data regarding the absolute number of distant metastases were provided in all trial reports. A significant benefit in favor of the addition of chemotherapy was found (P Ͻ .0001) for all studies, with an RR of 0.72 (95% CI, 0.62 to 0.84; Fig 4) . In the three studies that compared radiotherapy with concomitant chemotherapy, a significant benefit was found in favor of the combined treatment (P ϭ .01), with an RR of 0.70 (95% CI, 0.54 to 0.92). When only the two studies were taken into account using concomitant chemotherapy alone, the RR was 0.75 (95% CI, 0.56 to 0.99), which was still statistically significant (P ϭ .04). The addition of neoadjuvant chemotherapy to radiation also resulted in a significant reduction (P ϭ .0003) of the incidence of distant metastases, with an RR of 0.67 (95% CI, 0.54 to 0.83). Again, no significant beneficial effect on the incidence of distant metastases was found for adjuvant chemotherapy (RR, 0.89; 95% CI, 0.64 to 1.26).
DISCUSSION
This systematic review, comparing radiotherapy alone with radiation combined with chemotherapy in locally advanced NPC, revealed a positive effect of the addition of chemotherapy to radiation. The addition of chemotherapy not only significantly reduced the risk of locoregional recurrence and distant metastasis, but also significantly improved the overall survival. However, the patterns of the results suggest that concomitant chemotherapy with radiation is the most effective approach to combine chemotherapy and radiation in NPC. Moreover, the subgroup analysis showed that a significant beneficial effect on the overall survival was only found for those studies that used concomitant chemoradiotherapy with or without adjuvant chemotherapy and not for induction or adjuvant chemotherapy alone. These results are in line with those found for non-NPC in the head and neck region, 1, 6 showing that the major benefit from chemotherapy is conferred by concomitant chemotherapy to radiation rather than by neoadjuvant and/or adjuvant chemotherapy. It has to be taken into account that the data on overall survival were only available in two out of three studies in which concomitant chemoradiotherapy was part of the experimental arm. In the study without information regarding the overall survival, 9 no significant beneficial effect was noted with regard to the progression-free survival and the risks of local recurrence and distant metastases. However, a significant interaction term was found, indicating that the benefit of concomitant chemotherapy to radiation was beneficial in International Union Against Cancer criteria T3/T4 tumors but not in the subset of patients with International Union Against Cancer criteria T1/T2 tumors. Therefore, the estimation of the mortality reduction and the absolute survival benefit of 20% after Forest plot of the hazard ratio of the overall survival with radiotherapy (RT) alone versus radiotherapy plus chemotherapy (CHT). The studies were divided according to the sequence of radiotherapy and chemotherapy. The estimate of the hazard ratio of each individual trial corresponds to the middle of the squares and the horizontal line gives the 95% CI. On each line, the number of events as a fraction of the total number randomized are shown for both treatment groups, along with the estimates of the (OϪE ) and the variance. For each subgroup (ie, neoadjuvant, concomitant, and adjuvant chemotherapy), the sum of the statistics, along with the summary hazard ratio (HR), is represented by the middle of the open diamonds. A test of heterogeneity between the trials within a subgroup is given below the summary statistic. The lower part of the plot represents the overall tests. The closed diamond shows the overall hazard ratio with its 95% CI. ( 1 ), relative risk (RR) based on three studies (concomitant Ϯ adjuvant chemotherapy); ( 2 ), RR based on two studies (concomitant chemotherapy alone). Var, variance; (OϪE ), observed minus expected.
3 years as found in this analysis will probably be somewhat overestimated.
The results of this analysis indicate that there is a possible difference in efficacy between neoadjuvant and adjuvant chemotherapy, in particular with regard to the risk of distant metastases. For adjuvant chemotherapy, there was no significant reduction in the risk of locoregional recurrence and/or distant metastases, and no improvement of the overall survival. However, the addition of neoadjuvant chemotherapy to radiation significantly reduced the risk of locoregional recurrence and distant metastases, which was not translated into a significant improvement of the overall survival. It should be noted that the relative risk for locoregional recurrence as observed for neoadjuvant and adjuvant chemotherapy were approximately the same. Thus, the lack of statistical significance with regard to locoregional recurrence for adjuvant in comparison with neoadjuvant chemotherapy could well be explained by a difference in statistical power resulting from the smaller number of patients included in the adjuvant subgroup (n ϭ 463) compared with the neoadjuvant subgroup (n ϭ 1,209). However, a significant interaction term was present regarding the percent reduction in the relative risk of distant metastases, indicating that neoadjuvant chemotherapy was more efficient in reducing the risk of distant metastases than was adjuvant chemotherapy. One of the possible explanations for this apparent contradiction could be a difference in efficacy of the chemotherapy regimens used in the trials included in the two subgroups, although the heterogeneity of the regimens used precludes additional analysis on this subject. For instance, the largest adjuvant study by Rossi et al, 17 which accounts for half of the patients in this subgroup, is the only trial in this metaanalysis that used a non-platinum-based regimen. Furthermore, in this particular study, only patients in complete response after radiation were randomly assigned, which means patients with more radiocurable disease were selected. Another explanation could be that patients' compliance with neoadjuvant chemotherapy was much higher compared with that observed with adjuvant chemotherapy (Table 2) . Low compliance was also observed in the Intergroup study, in which the compliance to the adjuvant part was only 55%. 3 The most frequently mentioned reason for noncompliance was refusal by the patient to undergo additional treatment and/or toxicity, 3, 11 which is in accordance with our own institutional experience with the Intergroup regimen.
One of the shortcomings of our study is that only published studies were included in the analysis instead of individual patient data, which may result in two sources of bias. First, publication bias occurs, because trials with a statistically significant effect are more likely to be published than are negative trials, thus leading to an overestimation of the size of the difference. Second, selection bias occurs because some patients may have been excluded from the analysis presented in the publication for treatment-related reasons. Moreover, other advantages of a meta-analysis using individual patient data are the possibility of quality control of the individual patient data, the possibility of using updated follow-up data, and the possibility of subgroup (eg, different chemotherapy regimens) and prognostic factor analysis.
The majority of trials included in this meta-analysis are performed in geographic areas where NPC is endemic.
9-12,14,15 It still remains unclear whether the results obtained from trials performed in these endemic areas can be extrapolated to nonendemic areas and vice versa. On the basis of the report by Chan et al, 9 who, in contrast to the findings in the Intergroup study, did not find a significant benefit on progression-free survival by using concurrent chemoradiotherapy instead of radiotherapy alone, it has been suggested that the addition of chemotherapy confers more benefit for differentiated WHO grade 1 tumors than for undifferentiated WHO grade 3 tumors. 18 However, in the more recent report by Lin at al, 15 in which only patients with advanced undifferentiated NPC were randomly assigned between radiotherapy alone and concomitant chemoradiotherapy, a significant improvement of both progression-free and overall survival was found. This study was the first showing a benefit of concurrent chemotherapy in an endemic area. Furthermore, in this meta-analysis, no significant heterogeneity within the subgroups between the individual studies was found.
At present, it still remains difficult to assess the most optimal approach to incorporate chemotherapy with radiation in NPC. On the basis of these results, concomitant chemotherapy in addition to radiotherapy appears to be most effective and significantly reduces the risk of locoregional failure and distant metastasis, and significantly improves the overall survival, but at the cost of more acute radiationinduced and chemotherapy-related toxicity.
3,9,15 It should be noted that information with regard to late radiation-induced morbidity after concomitant chemoradiotherapy in comparison with radiation alone is scarce. The usefulness of adjuvant chemotherapy, which is still part of the Intergroup regimen, is questionable. In the present meta-analysis, no benefit was found for adjuvant chemotherapy for any of the end points. This is also supported by the preliminary results of a randomized study from Kwong et al. 19 In this study, patients were randomly assigned to receive radiotherapy alone, concomitant chemoradiotherapy (tegafur plus uracil), and adjuvant chemotherapy (alternating cisplatin and fluorouracil plus vincristine, bleomycin, and methotrexate) using a 2 ϫ 2 factorial design. The addition of concomitant chemotherapy significantly improved the locoregional control, distant-metastasisfree survival, and the relapse-free survival, whereas no benefit was noted with adjuvant chemotherapy.
Does the addition of more effective neoadjuvant chemotherapy to concomitant chemoradiotherapy lead to an additional improvement of the overall survival in NPC? Taking into account the chemotherapy regimens used, there seems to be room for improvement. In one study in which the additional role of neoadjuvant chemotherapy was investigated, an excess of treatment-related deaths in the neoadjuvant arm was noted (8%). 13 In other studies, the dose of chemotherapy and number of courses was relatively low.
12,14 Possibly, more effective neoadjuvant chemotherapy could further improve the treatment results in NPC, but such an approach needs additional investigation.
In conclusion, concomitant chemotherapy in addition to radiation is the most effective way to improve the overall survival in NPC. Neoadjuvant chemotherapy significantly reduced the risk of locoregional recurrence and distant metastases; therefore, the addition of induction chemotherapy to concomitant chemoradiotherapy warrants additional investigation. The exact role of adjuvant chemotherapy remains unclear because it has not been adequately tested and compliance is difficult.
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